Summit X LLC’s Idexx Laboratories IDXX Stock Holding History

Summit X LLC’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10	Closed	-$393	–	326
2020 Q3	$393	Buy	+10	New	+$3.7K	0.01%	339

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Summit X LLC's IDXX Position: Q4 2020 in Review

Summit X LLC sold out of Idexx Laboratories (IDXX) in Q4 2020, closing a stake of 10 shares — an estimated $393 sold.

Summit X LLC first reported a position in IDXX in Q3 2020 and held it in 1 quarter. The position peaked at $393 in Q3 2020. 971 funds tracked by Wall St. Rank hold IDXX as of Q4 2020.

Summit X LLC reported no remaining Idexx Laboratories position as of Q4 2020 after selling out during the quarter.
Summit X LLC sold 10 Idexx Laboratories shares in Q4 2020, an estimated $393.
Summit X LLC first reported a position in Idexx Laboratories in Q3 2020 and held it in 1 quarter.
Summit X LLC's Idexx Laboratories position peaked at $393 in Q3 2020.
971 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2020.

Based on Summit X LLC's 13F filing for Q4 2020, filed 29 Jan 2021.